Prime Medicine, Inc. (PRME)
3.67
+0.10
(+2.80%)
USD |
NASDAQ |
Sep 02, 16:00
3.70
+0.03
(+0.82%)
Pre-Market: 20:00
Prime Medicine Research and Development Expense (TTM) : 146.20M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 146.20M |
| March 31, 2026 | 154.18M |
| December 31, 2025 | 160.64M |
| September 30, 2025 | 160.03M |
| June 30, 2025 | 156.38M |
| March 31, 2025 | 158.08M |
| December 31, 2024 | 155.29M |
| September 30, 2024 | 162.64M |
| June 30, 2024 | 163.27M |
| March 31, 2024 | 154.80M |
| Date | Value |
|---|---|
| December 31, 2023 | 147.90M |
| September 30, 2023 | 135.51M |
| June 30, 2023 | 119.59M |
| March 31, 2023 | 103.93M |
| December 31, 2022 | 86.72M |
| September 30, 2022 | 110.55M |
| June 30, 2022 | 92.91M |
| March 31, 2022 | 79.66M |
| December 31, 2021 | 70.55M |
| September 30, 2021 | 18.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Beam Therapeutics, Inc. | 408.66M |
| Twist Bioscience Corp. | 71.86M |
| Sana Biotechnology, Inc. | 129.50M |
| Intellia Therapeutics, Inc. | 337.63M |
| Revolution Medicines, Inc. | 1.287B |